Lisocabtagene maraleucel
Phase 2Cell therapy
Bristol-Myers SquibbLisocabtagene maraleucel is a cell therapy that works as a CD19 CAR-T.[2] It is being investigated across 5 indications, with its most advanced program in Phase 2.[1]
Lisocabtagene maraleucel is one of 163 cell therapy programs targeting Lymphoma. It is currently in Phase 2.
5
Indications
16
Total Trials
12
Active Trials
162
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Lisocabtagene maraleucel
Bristol-Myers SquibbPhase 2
Blenoxane
SSequus Pharmaceuticals
Preclinical
Velban
EEastern Cooperative Oncology Group
Preclinical
Zofran
NovartisPreclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma5 trials
Cell Therapy2 trials
Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma2 trials
Richter's Transformation1 trial
Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation
Recruiting·—·Phase 2·NCT05672173·20 enrolled
5 more indications
Second-line Therapy1 trial
Diffuse Large B-Cell Lymphoma1 trial
Follicular Lymphoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lisocabtagene maraleucel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- CD19 CAR-T[2]
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 2[1]
- Company